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Background-—The cysteine protease cathepsin K (CatK) has been implicated in the pathogenesis of cardiovascular disease. We
sought to determine the link between atrial ﬁbrillation (AF) and plasma CatK levels and to investigate the expression of and
therapeutic target for CatK in vivo and in vitro.
Methods and Results-—Plasma CatK and extracellular matrix protein peptides (intact procollagen type I of N-terminal propeptide;
carboxyl-terminal telopeptide of type I collagen [ICTP]) were measured in 209 consecutive patients with AF (paroxysmal AF, 146;
persistent AF, 63) and 112 control subjects. In addition, the regulation of CatK expression was investigated in vivo and vitro.
Patients with AF had higher plasma CatK and ICTP levels than did control subjects. Patients with persistent AF had higher levels of
plasma CatK and ICTP than did patients with paroxysmal AF. CatK was correlated with ICTP concentration and left atrial diameter in
all subjects. In rabbits, superoxide production, CatK activity, ﬁbrosis, and the levels of atrial tissue angiotensin II, angiotensin type
1 receptor, gp91phox, phospho-p38 mitogen-activated protein kinase, and CatK were greater in those with tachypacing-induced AF
than in controls, and these changes were reversed with angiotensin type 1 receptor antagonist. Olmesartan and mitogen-activated
protein kinase inhibitor decreased the CatK expression induced by angiotensin II in rat neonatal myocytes.
Conclusions-—These data indicated that increased plasma CatK levels are linked with the presence of AF. Angiotensin type 1
receptor antagonist appears to be effective in alleviating atrial ﬁbrosis in a rabbit AF model, partly reducing angiotensin type 1
receptor-p38mitogen-activated protein kinase-dependent and -independent CatK activation, thus preventing AF. (J Am Heart
Assoc. 2013;2:e000503 doi: 10.1161/JAHA.113.000503)
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A
trial ﬁbrillation (AF) is the most common cardiac
arrhythmia in clinical practice. AF itself has been shown
to cause changes in the function and structure of the atria,
providing a possible explanation for the progressive nature of
this arrhythmia.
1–3 In the atria, the extracellular matrix
provides supportive scaffolding for cardiomyocytes, maintains
the structural integrity of cardiac tissue, and is necessary for
electrical conduction via cardiomyocytes.
4 Growing evidence
supports the concept that structural remodeling of the
extracellular matrix may be the key event leading to the
development of AF and atrial mechanical dysfunction. Lysos-
mal protease cathepsins (Cats) traditionally have been known
to degrade unwanted intracellular or endocytosed proteins.
5
However, the recent recognition of the inducible CatK and
CatS has revealed their proteolytic functions in inﬂammatory
disease, including atherosclerosis-based vascular disease
processes.
6–8 More recently, several studies have reported
that Cats play a functional role in intracellular and extracel-
lular protein degradation in cardiac myocytes by contributing
to matrix turnover, chamber dilation, and structural remodel-
ing.
9–12 A few reports suggest that circulating Cats have a
predictive value for proteolysis-associated disease, and
related research has focused on vascular disease (including
coronary artery diseases and aortic aneurysm).
13,14 To date,
no studies have examined atrial Cat expression and plasma
levels as potential biomarkers for atrial remodeling in atrial
disease.
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ORIGINAL RESEARCHRecently, activation of the renin–angiotensin system has
been implicated as part of the mechanism of AF.
15 Cardiac-
speciﬁc overexpression of angiotensin-converting enzyme in
mice results in excessive levels of cardiac angiotensin II (Ang
II), and the mice develop spontaneous AF.
16 Ang II has
numerous cardiovascular effects that might lead to cardiac
arrhythmia, including the induction of ﬁbrosis and the prolif-
eration of cardiac ﬁbroblasts, the increased synthesis of
collagen, and the promotion of reactive oxygen species
generation.
17 Ang II has been shown to induce p38mitogen-
activated protein kinase (p38MAPK)/extracellular signal-regu-
lated kinase activation and atrial interstitial ﬁbrosis.
18,19
Several recent studies have demonstrated that angiotensin
inhibition prevents left ventricular ﬁbrosis by decreasing
the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase–dependent Cat activation.
11,20 Although the inhibition
of Ang II through the use of Ang II type 1 receptor (AT1R)
antagonists or angiotensin-converting enzyme inhibitors has
preventedAFinanimalmodelsandadiversehumanpopulation
with AF or at risk of developing AF,
21–24 the underlying
mechanism is poorly understood.
In this study, we sought to determine whether circulating
CatK levels are closely linked to the presence of AF and
increased levels of the collagen type I degradation marker. In
addition, we explored the possible mechanisms by which Ang
II inhibition mitigates atrial remodeling and AF in a rabbit
tachypacing model.
Methods
Study Population
We recruited 209 consecutive patients with paroxysmal AF
(PAF; n=146) or persistentAF (PeAF; n=63) who were admitted
to Nagoya University Hospital between March 2009 and
December 2010 for scheduled radiofrequency catheter abla-
tion with coronary angiography. AF in these patients had been
diagnosed in light of symptoms, 12-lead electrocardiogram,
and Holter electrocardiogram. As described previously,
25 PAF
was deﬁned on the basis of a history of 1 or more episodes of
AF that self-resolved or were terminated medically within
7 days, and PeAF was deﬁned according to a history of 1 or
more episodes of AF over 7 days that required pharmacolog-
ical or electrical cardioversion to establish normal sinus
rhythm. None of the patients in this study had permanent AF.
We excluded patients with dilated or hypertrophic cardiomy-
opathy, myocardial infarction, congenital heart disease, con-
gestive heart failure, or valvular heart diseases and those
receiving hemodialysis. AF patients were receiving standard
therapy with antiarrhythmic drugs, b-blockers, angiotensin-
converting enzyme inhibitors or AT1R blockers, and statins at
the time they underwent ablation. We also assessed 112
subjects with and without paroxysmal atrial arrhythmia (no
previously documented AF), who were considered to represent
the control group. The study protocol was approved by the
ethics committee of the Nagoya University School of Medicine,
and written informed consent was obtained from all patients.
Laboratory Assay
Laboratory measurements were performed under blinded
conditions. Human and rabbit plasma CatK levels were
determined by using ELISA kits (Biomedica Gruppe, Biomedica
Medizinprodukte). Serum interleukin-1b levels were measured
by using commercially available kits. Serum levels of intact
procollagen type I N-terminal propeptide (I-PINP), carboxyl-
terminal telopeptide of collagen type I (ICTP), atrial natriuretic
peptide, cystatin C, high-sensitivity C-reactive protein, hemo-
globin A1c, and atrial tissue Ang II were measured at a
commercial laboratory (SRL [Tokyo, Japan]). Plasma CatK
valueswereexpressedasng/mL,andinterassayandintraassay
coefﬁcients of variation were <8% (n=20).
Echocardiography
Two-dimensional and Doppler echocardiography was per-
formed by an experienced sonographer using a Vivid4 System
(GE Healthcare Bio-Sciences). The images were recorded on a
DVD recorder and analyzed ofﬂine. Left atrial diameter (LAD)
was obtained by using standard M-mode measurements, as
recommended by the American Society of Echocardiography.
The left ventricular ejection fraction was calculated using the
modiﬁed Simpson’s rule.
Animal Model and Treatment
A rabbit AF model was induced by ventricular tachypacing as
describedpreviously.
26Thestudyprotocolwasapprovedbythe
Institutional Animal Care and Use Committee of Nagoya
University School of Medicine. Eleven-week-old male New
Zealand White rabbits (Kitayama Labs) underwent surgery with
or without the implantation of right ventricular pacemakers
(Medtronic) under anesthesia with ketamine hydrochloride
35 mg/kg and xylazine 3 mg/kg. After the animals recovered
from surgery, the pacemakers were programmed to pace at
380 beats/min for 4 weeks. Rabbits were divided into 3
groups as follows: nonpaced control rabbits (control rabbits;
n=7), rabbits subjected to ventricular tachypacing treated with
vehicle (0.5% carboxymethylcellulose, AF rabbits; n=7), and
rabbits subjected to tachypacing with olmesartan treatment
(Olm rabbits; n=5). Daily oral administration of olmesartan
(1 mg/kg;Daichi-Sankyo)viagastrictubewasinitiated1 week
before surgery and continued throughout the study period.
Electrocardiograms were monitored once per week to adjust
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capture in each rabbit. At the end of 4 weeks of ventricular
tachypacing, open chest electrophysiological studies were
performed under anesthesia and ventilated mechanically with
isoﬂurance-containing room air (0.5% per 2 L/min) as
described previously.
26 After electrophysiological evaluation,
bothatriawereharvestedforbiologicandhistologicalanalyses.
Western Blotting
On postoperative day, tissue samples obtained on operative
day 28 were homogenized lysis buffer containing 20 mmol/L
Tris-HCl, pH 7.4, 1% Nonidet P-40, 150 mmol/L NaCl, 0.5%
deoxycholic acid, 1 mmol/L sodium orthovanadate, and
protease inhibitor mixture (Sigma). The protein content was
determined by using the Bradford method. The same amount
of protein (40 lg) was loaded per lane and separated using
denaturing 10% polyacrylamide gels. The membranes were
probed with antibodies to CatK,
27 to AT1R (Santa Cruz
Biotechnology), to gp91phox (BD Biosciences), and to total
p38MAPK and phosphorylated p38MAPK (p-p38MAPK) (Cell
Signaling Technology, Inc). Bands were visualized using
chemiluminescence (ECL Western Blotting Detection Kit,
Amersham Biosciences).
Immunohistochemistry
On postoperative day 28, transverse sections (5-lm thickness)
of atrial tissues were stained with rabbit polyclonal antibody to
CatK (dilution, 1:100) as described previously.
27 As a negative
control, the primary antibody was replaced by nonimmune
immunoglobulin G (Vector). Azan Mallory staining was applied
to evaluate ﬁbrotic deposition in rabbit atria. We set a
threshold to automatically compute the blue pixel area for the
histochemical stain and then computed the ratio (percent) of
the positively stained area to the total cross-sectional atrial
free-wall area using BZ-II Analyzer, Exe 1.42 software
(Keyence). Three random microscopic ﬁelds (9400) from 8
independent cross sections of atrial free-wall (24 ﬁelds) in
each animal were quantiﬁed and averaged for each animal.
Assay of Superoxide Production
Speciﬁc NADPH oxidase activity of total homogenates of fresh
left atrial tissue was measured with the use of a lucigenin-
based enhanced chemiluminescence assay as described.
20 A
low lucigenin concentration (5 mmol/L) was used to minimize
artifactual O2
 production attributable to redox cycling. In
brief, homogenate protein (1 mg) lysis buffer (1 mL;
20 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L ethylene glycol tetraacetic acid, and 1%
Triton X-100) was transferred to an assay tube, and NADPH
and dark-adapted lucigenin were added to ﬁnal concentra-
tions of 100 and 5 mmol/L, respectively, immediately before
the measurement of chemiluminescence. All assays were
performed in triplicate. The chemiluminescence signal was
sampled every minute for 12 minutes using a tube luminom-
eter (20/20; Turner Biosystems), and the respective back-
ground counts were subtracted from the experimental values.
Cell Culture and Simulation
Neonatal rat atrial myocytes from 1-day-old Wistar rats were
isolated as described previously
28 and cultured in a mixture
(50:50, v/v) of Dulbecco’s modiﬁed Eagle’s medium and
Ham’s F-12 (Invitrogen) supplemented with 10% fetal bovine
serum and antibiotics.
11 After 24 hours of culture, the cells
(5910
4/well in 12-well plates) were pretreated with or
without various reagents for appropriate amounts of time, and
the cells were subjected to the related biologic assays.
11
Gene Expression Assay
Total RNA was isolated cultured cells and was subjected to
reverse transcription with a PCR Core kit (Applied Biosys-
tems). The resulting cDNA was subjected to quantitative real-
time PCR analysis with targeted gene primers and with use of
the ABI 7300 Real-Time PCR System under the following
conditions: 50°C (2 minutes) for UNG incubation, 94°C
(10 minutes) for AmpliTaq Gold activation, 95°C (15 sec-
onds), and 59°C (1 minute) for 40 cycles as previous
described.
27 The amount of each mRNA was normalized
against the corresponding amount of glyceraldehyde-3-phos-
phate dehydrogenase mRNA.
Assay of Collagenolytic Activity
Total protein (100 lg) from the extracts of cells and atrial
tissues was incubated with 500 lg/mL ﬂuorescein-labeled
type I collagen (Molecular Probes Inc) for 6 hours. Reactions
were performed in the absence or presence of several
protease inhibitors at indicated concentrations as described
previously.
29
Statistical Analysis
Summary descriptive statistics for continuous parameters
are presented as meanSD values. Categorical variables
were compared among study groups by using the
v2 test.
Student’s t test (for comparison of continuous parameters
between 2 groups) or 1-way ANOVA (for comparison of
continuous parameters among 3 or more groups), followed
by Tukey’s post-hoc test, was used to test signiﬁcant
differences. Cystatin C and high-sensitive C-reaction protein
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the data showed a skewed distribution. If the homogeneity
of the variance assumption was violated, the nonparametric
Kruskal–Wallistestwasusedinstead.Thefactorsthatrelatedat
the P<0.1 level were selected as independent variable candi-
dates for multiple logistic regression analysis and were used to
evaluate the independent contribution of clinical parameters to
AF. Correlation coefﬁcients were calculated using linear
regression analysis. In animal and in cell experiments, we
performed the text related to ensuring normality for the tests
with very small sample sizes. StatFlex(version 6.0; Artech) was
used for all statistical analysis. P values of <0.05 were
considered statistically signiﬁcant.
Results
All Patients
The baseline clinical and demographic features of the study
population are shown in Table 1. The AF group was older and
had more men than did the control group (P<0.001). There
were no differences between the AF and control groups in
potential causal factors. AF patients had taken more
b-blockers than had the control subjects (P=0.02). Patients
with AF had signiﬁcantly (P<0.05) larger LADs and worse
ejection fractions than did control subjects.
Compared with controls, patients with AF had signiﬁ-
cantly (P<0.001) higher plasma CatK, interleukin-1b, ICTP,
and I-PINP levels and lower I-PINP:ICTP ratios than did
control subjects. Compared with controls, AF patients had
higher levels of hemoglobin A1c (P<0.001), high-sensitive
C-reactive protein (P=0.04), and atrial natriuretic peptide
(P<0.001), whereas there were no signiﬁcant differences in
potassium or in low-density and high-density lipoproteins. In
all subjects, univariate regression analysis revealed that
there was a positive correlation between CatK and ICTP
(r=0.3, P<0.0001; Figure 1A) and LAD (r=0.4, P<0.0001;
Figure 1B).
PAF Versus PeAF
The baseline characteristics of the PAF and PeAF groups are
presented in Table 2. Patients with PeAF had larger LADs and
worse ejection fractions than did PAF patients (P<0.05). With
the exception of age, the percentage of women, chronic heart
failure, and use of statin treatments, there were no signiﬁcant
differences between the 2 groups. As expected, the PeAF
group had increased levels of plasma high-sensitive C-reactive
protein and atrial natriuretic peptide (P<0.05 for both)
compared with patients with PAF. In addition, the levels of
CatK, ICTP, and interleukin-1b were higher and the I-PINP:
ICTP ratio lower among subjects in the PeAF group compared
with those in the PAF group (P<0.05 for all comparisons;
Figure 2).
Biomarkers for Prediction of AF
Table 3 shows the results of the multiple logistic regression
analyses to assess the factors (included at the P<0.1 level in
Table 1. Patient Characteristics
AF (n=209)
Control
(n=112) P Value
Demographic Characteristics
Age, y 60.110.9 54.810.7 <0.001
Female, % 23.0 42.9 <0.001
Body mass index, kg/m
2 23.73.4 23.02.8 0.09
Smokers, % 30.1 23.2 0.25
Causal factors
Hypertension, % 45.5 38.4 0.26
Diabetes mellitus, % 20.1 12.5 0.09
Ischemic heart disease, % 8.1 3.6 0.12
Chronic heart failure, % 7.2 4.5 0.34
Echocardiography
Left atrial diameter, mm 39.06.9 32.34.9 <0.001
LV ejection fraction, % 61.88.4 77.16.9 0.002
Blood examination
Potassium, mEq/L 4.30.4 4.20.4 0.48
LDL, mg/dL 118.427.8 121.229.3 0.40
HDL, mg/dL 55.714.2 57.413.3 0.32
Hemoglobin A1c, % 5.60.7 5.20.7 <0.001
ANP, pg/mL 70.970.9 27.329.9 <0.001
hs-CRP, mg/dL 0.140.4 0.060.1 0.04
IL-1b, pg/mL 14.37.0 10.97.9 <0.001
I-PINP:ICTP 13.77.7 25.119.2 <0.001
ICTP, ng/mL 3.82.7 1.51.3 <0.001
CatK, ng/mL 13.16.7 6.13.9 <0.001
Medications
ACEIs, % 4.3 8.0 0.17
ARBs, % 30.1 26.8 0.53
CCBs, % 20.1 17.0 0.50
b-Blockers, % 29.7 8.9 0.02
Statins, % 20.1 22.3 0.64
Antiarrhythmic drugs, % 100 0
Values are expressed as meanSD. AF indicates atrial ﬁbrillation; LV, left ventricular;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; ANP, atrial natriuretic
peptide; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; I-PINP, intact
procollagen type I N-terminal propeptide; ICTP, carboxyl-terminal telopeptide of type I
collagen; CatK, cathepsin K; ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; CCB, calcium channel blocker.
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the multiple logistic regression analyses, only LAD (odds ratio,
1.19; 95% CI, 1.06 to 1.36; P<0.05), CatK (odds ratio, 1.27;
95% CI, 1.10 to 1.39; P<0.01), and I-PINP:ICTP (odds ratio,
0.79; 95% CI, 0.69 to 0.90; P<0.001) were signiﬁcantly
associated with AF.
Inhibitory Effect of AT1R Antagonism on CatK
Expression and Atrial Remodeling With AF
Immunostaining showed that the expression of CatK was
markedly increased throughout the atrial tissue of AF rabbits,
with apparent expression in the myocytes, and this change
was inhibited by olmesartan (Figure 3A). As shown in Figure
3B, collagenolytic activity was higher in AF rabbits than in
controls, and this change was more sensitive to a speciﬁc
CatK inhibitor (CatK-II) and the broad-spectrum cysteine
protease E64 than to GM6001, an inhibitor of matrix
metalloproteinases (Figure 3B). Olmesartan reduced the
amount of increased collagenolytic activity in the atrial
extract of AF rabbits (0.560.09 versus 0.940.19 ﬂuores-
cence intensity, P<0.01).
AF rabbits had increased levels of NADPH oxidase activity
(Figure 3C) and of an NADPH oxidase subunit, gp91phox
protein (Figure 3D; P<0.01). As shown in Figure 3D and 3E,
Western blotting revealed that the levels of CatK, AT1R, and
p-p38MAPK proteins were greater in AF rabbits than in
controls (P<0.01). All of these changes were reversed with
olmesartan (P<0.01). In addition, rabbits with AF had
signiﬁcantly higher atrial tissue Ang II levels than did control
rabbits (78.36.0 versus 36.24.8 pg/100 mg, P<0.01),
and this effect was also reduced by olmesartan (45.13.7
versus 78.36.0, P<0.05). The duration of AF was
11.80.2 seconds in ventricular-tachypaced rabbits, whereas
AF was not induced in nonpaced controls (Figure 4A). The
duration of AF was signiﬁcantly reduced in olmesartan-
treated rabbits (3.20.1 seconds) compared with ventricular
tachypacing–only rabbits (P<0.01). Furthermore, olmesartan
signiﬁcantly suppressed atrial ﬁbrosis compared with the
control group (3.90.6 versus 9.81.6%, P<0.05) (Figure 4B
and 4C).
Quantitative real-time PCR demonstrated that both H2O2
and Ang II signiﬁcantly (P<0.05) enhanced CatK mRNA
expression and that olmesartan reduced CatK expression in
response to Ang II in cultured rat neonatal atrial myocytes
(Figure 5A). Ang II enhanced the collagenolytic activity in cells
extracts, and this effect was sensitive to CatK-II and E64
(Figure 5B). Western blots showed olmesartan-mediated
reductions in the level of Ang II–induced CatK, gp91phox,
and p-p38MAPK (Figure 5C). Furthermore, Ang II–induced
CatK gene expression was suppressed (P<0.001) by olme-
sartan as well as by NADPH oxidase inhibitor apocynin and
p38 inhibitor SB202190 (Figure 5D). Furthermore, apocynin
markedly enhanced MAPK inhibitor–mediated action.
Discussion
Plasma Biomarkers of CatK and Collagen
Turnover and AF
Several studies have examined the effect of myocardial
collagen turnover on the pathogenesis of AF and the outcome
of AF ablation.
26,30,31 Multiple lines of evidence indicate that
CatK is the most abundant and important cysteinyl enzyme
synthesized by the cardiovascular system and that it is
relevant to cardiovascular disorders, including atherosclero-
sis,
6–8 osteoarthritis,
32 and heart failure.
27 To the best of our
knowledge, this is the ﬁrst study to show that patients with AF
had higher levels of plasma CatK than did control subjects. In
agreement with this observation, CatK levels and CatK-related
Figure 1. Correlations between plasma levels of CatK and ICTP (A) and (B) LAD. In all patients, there were positive correlations between plasma
levels of cathepsin (CatK) and carboxyl-terminal telopeptide of type I collagen (ICTP) and left atrial diameter (LAD).
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atrial tissue of rabbits with tachypacing-induced AF. Univar-
iate regression analysis showed a positive correlation
between plasma ICTP and CatK levels. Moreover, multivariable
logistic regression analysis clearly showed that CatK and the
I-PINP:ICTP ratio were independent predictors of AF. Coupled
with several recent studies showing increased serum levels of
several Cats (S and L) in association with ischemic heart
disease,
8,14 our ﬁndings indicate that elevated plasma levels
of CatK with a collagen metabolism–related index (I-PINP:ICTP
ratio) can serve as a novel marker of AF and a noninvasive
method of documenting the mechanisms of atrial ﬁbrosis in
AF.
Patients initially presenting with PAF often exhibit disease
progression and eventually develop PeAF.
1 Although the exact
pathophysiological mechanisms remain unclear, the persis-
tence of AF is thought to result from atrial remodeling.
3,30
Increasing evidence suggests that atrial ﬁbrosis, which has a
slower time course than does AF, may be involved in the
development and recurrence of AF.
1,30 In the current study,
CatK and ICTP (a marker of collagen degradation) levels were
higher, but the I-PINP:ICTP ratio was lower, in the PeAF group
than in the PAF group. Interestingly, CatK levels were
positively correlated with LAD, and patients with PeAF had
larger LADs than did those with PAF. These ﬁndings imply
that—in addition to the duration of arrhythmia—impaired
Table 2. Patient Characteristics
Control (n=112) PAF (n=146) PeAF (n=63) ANOVA (P Value)
Demographic characteristics
Age, y 54.810.7 61.110.6* 57.811.3*
‡ 0.04
Female, % 42.9 27.4* 12.7
†‡ <0.001
Body mass index, kg/m
2 23.02.8 3.53.5 24.03.1 0.21
Smoker, % 23.2 28.1 34.9 0.31
Causal factors
Hypertension, % 38.4 46.6 42.9 0.48
Diabetes mellitus, % 12.5 21.9 15.9 0.47
Ischemic heart disease, % 3.6 7.5 9.5 0.25
Chronic heart failure, % 4.5 3.4 15.9
†‡ 0.002
Echocardiography
Left atrial diameter, mm 32.34.9 37.26.1 43.17.0
†‡ <0.001
LV ejection fraction, % 77.16.9 63.57.6* 58.09.0
†‡ <0.001
Blood examination
Potassium, mEq/L 4.60.4 4.21.5 4.31.3 0.06
LDL, mg/dL 121.329.3 120.026.5 114.730.4 0.24
HDL, mg/dL 57.413.3 55.915.1 55.311.8 <0.001
Hemoglobin A1c, % 5.20.7 5.60.6* 5.60.8* 0.89
hs-CRP, mg/dL 0.060.1 0.140.1* 0.160.2
†‡ 0.02
ANP, pg/mL 27.329.9 59.569.9* 97.366.4
†‡ <0.001
Cystatine C, mg/L 0.90.3 1.00.2 1.10.9 0.23
Medications
ARBs or ACEIs, % 34.8 37.7 27.0 0.08
CCBs, % 17.0 19.9 20.6 0.05
b-Blockers, % 8.9 30.8* 27.0* 0.01
Statins, % 22.3 25.3 7.9
†‡ 0.01
Values are expressed as meanSD. PAF indicates paroxysmal atrial ﬁbrillation; PeAF, persistent atrial ﬁbrillation; LV, left ventricular; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; hs-CRP, high-sensitivity C-reactive protein; ANP, atrial natriuretic peptide; ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium
channel blocker.
*P<0.05 compared with control value.
†P<0.01 compared with control values.
‡P<0.05 compared with value for PAF vs PsAF patients.
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one of the initiating factors for AF. However, it should be
noted that there are also other initiating factors such as the
pulmonary veins for the initiation and maintenance of AF.
30
Ang II Inhibition Alleviates Structural Remodeling
Related to AF
Many of the Ang II–induced actions in intracellular signaling
transduction pathways that regulate gene expression are
mediated by the activation and nuclear translocation of
MAPKs.
33,34 We have shown that Ang II promotes p38MAPK
phosphorylation and CatK expression in cultured rat neona-
tal atrial myocytes and that these effects are reversed with
olmesartan. An inhibitor of p38MAPK inhibited Ang
II–induced CatK gene expression. In vivo studies, AF rabbits
exhibited substantial protein expression of CatK accom-
panied by increased atrial levels of Ang II, AT1R, and
phosphorylated p38MAPK proteins, and these changes were
reversed by olmesartan. Thus, AT1R antagonism appears to
attenuate CatK expression through the AT1R-p38MAPK–
dependent signaling pathway in the atrial tissues of AF
rabbits. Recently, it was reported that the Cat inhibitor E64d
prevented hypertensive cardiac remodeling and dysfunction
in a Dahl rat model.
11 In this study, olmesartan attenuated
the duration of AF and atrial ﬁbrosis in tachypacing rabbits.
Furthermore, olmesartan reduced the increase in collagen-
olytic activity in the atrial tissue of AF rabbits. The data
from enzyme assays demonstrated that increased collagen-
olytic activity in both atrial tissues and neonatal atrial
myocyte–conditioned medium was attenuated by a CatK-
speciﬁc inhibitor as well as a broad-spectrum Cat inhibitor.
Coupled with several recent clinical trials showing the
prevention of AF with Ang II inhibition,
22,24 these ﬁndings
indicate that the attenuation of AT1R/p38MAPK-dependent
Figure 2. Box plot depiction of the differences in the levels of plasma CatK, I-PINP, ICTP, and IL-1b. Plasma levels of CatK, I-PINP, ICTP, and
IL-1b. Levels of (A) CatK and (B) ICTP gradually increased, whereas (C) the I-PINP:ICTP ratios decreased from control subjects to patients with PAF
to subjects with PeAF. D, IL-1b levels in control subjects differed from those in both PAF and PeAF patients. Boxes represent the median (black
line), 25th percentile, and 75th percentile of observed data; whiskers show the 5th and 95th percentiles of each group. Values are expressed as
meanSD. *P<0.01 vs control;
†P<0.01 vs PAF. CatK indicates cathepsin K; ICTP, carboxyl-terminal telopeptide of type I collagen; IL, interleukin;
I-PINP, intact procollagen type I of N-terminal propeptide; PAF, paroxysmal atrial ﬁbrillation; PeAF, persistent atrial ﬁbrillation.
Table 3. Independent Predictors of AF According to
Multivariable Logistic Regression Analysis
Odds Ratio Estimate 95% CI P Value
LAD 1.19 1.06 to 1.36 <0.05
CatK 1.27 1.10 to 1.39 <0.01
I-PINP/ICTP ratio 0.79 0.69 to 0.90 <0.001
AF indicates atrial ﬁbrillation; LAD, left atrial diameter; CatK, cathepsin K; I-PINP, intact
procollagen type I N-terminal propeptide; ICTP, carboxyl-terminal telopeptide of type I
collagen.
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HCatK expression and activity by Ang II inhibition could
represent a novel mechanism for the protection of structural
remodeling-related AF, at least in an animal model. In
addition, the data from our study and the ﬁndings of other
researchers
35,36 suggest that the inhibition of matrix
metalloproteinases also contributes to collagen metabolism
in atrial ﬁbrosis. To attain a deeper understanding of the
importance of CatK participation in this context, additional
Figure 3. CatK protein expression and NADPH oxidase activity in nonpaced control (NP), ventricular tachypacing (VTP), and ventricular
tachypacing plus administration of olmesartan (Olm) rabbits. A, Representative images for CatK immunostaining in the atrial tissues of NP, VTP,
Olm rabbits and negative controls (without primary antibody). B, ELISAs of collagenolytic activity in untreated atrial tissues or in those treated with
a broad-spectrum inhibitor of Cats (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane [E64], 20 lmol/L; Molecular Probes), a CatK-speciﬁc
inhibitor (CatK-II, 10 lmol/L), and an inhibitor of matrix metalloproteinases (GM6001, 10 lmol/L; both from Calbiochem). Recombinant matrix
metalloproteinase 1 (rMMP-1) was included as a positive control. C, Chemiluminescence showing NADPH oxidase activity in atrial tissues from 3
groups. D, Representative Western blots and (E) quantitative data showing the levels of CatK, AT1R, gp91phox, p-p38MAPK, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) in left atrial tissue from rabbits. Analyzed animal numbers indicated on related bars. Scale bars indicate
50 lm. Values are expressed as meanSEM. *P<0.01 vs NP;
†P<0.01,
‡P<0.001 vs VTP. AF indicates atrial ﬁbrillation; AT1R, angiotensin type 1
receptor; CatK, cathepsin K; NADPH, nicotinamide adenine dinucleotide phosphate.
Figure 4. A, Duration of AF in NP, VTP, and olmesartan (Olm)-treated rabbits. B, Representative images and quantitative data show interstitial
ﬁbrosis in the right atrial tissues of 3 experimental groups. Analyzed animal numbers indicated on related bars. Scale bars indicate 100 lm.
Values are expressed as meanSEM. *P<0.01 vs control;
†P<0.01 vs VTP. AF indicates atrial ﬁbrillation; NP, nonpaced control; VTP, ventricular
tachypacing.
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Hexperiments using animals with conditional gene knockout
may be necessary.
Cross-talk Between NADPH Oxidase
and Ang II/AT1R Signaling Pathway
NADPH oxidase has been implicated in the pathogenesis of
cardiovascular disease.
37,38 Our data show that the abun-
dance and activity of the NADPH oxidase and its subunit
gp91phox markedly increased in the atria from rabbits with
AF. In vitro, we observed that both Ang II and H2O2
enhanced CatK expression and activity in cultured neonatal
atrial myocytes. Furthermore, NADPH oxidase inhibition with
apocynin showed an inhibitory effect on CatK expression in
response to Ang II. Because Ang II inhibition attenuated CatS
expression and activation via the reduction of NADPH
oxidase activity in cultured macrophages,
6 we propose that
superoxide generation by NADPH oxidase, through “cross-
talk” with the Ang II signaling pathway, can regulate the
proteolytic activity of CatK as well as contribute to the
pathophysiology of AF. This notion is supported by current
and previous ﬁndings that AT1R antagonism attenuated
atrial and ventricular remodeling and ﬁbrosis associated with
NADPH oxidase–derived superoxide production and CatK
expression and activation.
11,20 It is noteworthy that apocynin
enhanced SB202190-mediated inhibitory effects on CatK
expression in neonatal atrial myocytes. This effect raises the
possibility that NADPH-oxidase–derived O2
 signaling
directly affects CatK expression independent of the AT1R/
p38MAPK signaling pathway.
Figure 5. Regulation of CatK expression in cultured rat neonatal atrial myocytes. A, Quantitative real-time PCR assays showing the expression
of CatK mRNA levels in cultured cells treated with and without olmesartan (Olm, 1 lmol/L) in the presence of Ang II (1 lmol/L) or H2O2
(100 lmol/L) for 24 hours. B, Immunoﬂuorescence shows the collagenolytic activity induced by Ang II in cells left untreated or treated with CatK-
II (10 lmol/L) and E64 (10 lmol/L). C, Representative Western blots showing the levels of CatK, gp91phox, p-p38, and t-p38 induced by Ang II in
cultured neonatal atrial myocytes untreated or treated with Olm (p-p38MAPK and t-p38MAPK levels for 30 minutes; CatK and gp91phox levels for
24 hours). D, Quantitative PCR shows Ang II–mediated CatK mRNA expression in cells left untreated or treated with Olm (1 lmol/L), apocynin
(Apo, 100 lmol/L), SB202190 (SB, 10 lmol/L), or Apo+SB for 24 hours. Analyzed numbers indicated on related bars. Scale bars indicate
50 lm. Values are expressed as meanSEM. *P<0.05 vs control;
†P<0.01,
‡P<0.001 vs corresponding control. Ang indicates angiotensin II;
CatK, cathepsin K; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; rMMP1, recombinant matrix metalloproteinase 1.
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HStudy Limitations
Several limitations of the present study should be pointed out.
First, the small number of participants with and without AF
limited the power of this study to prove relationships and
differences and limited our power to conduct subgroup
analysis by PAF and PeAF. Second, the plasma markers of
CatK and collagen turnover are not atrial tissue speciﬁc. In
addition, patients with cardiomyopathy, myocardial infarction,
congenital heart disease, congestive heart failure, or valvular
heart diseases and those receiving hemodialysis were
excluded. It is unclear how their exclusion may have inﬂuenced
the present results. Third, despite our efforts to match the
control and AF groups, the AF patients were older and included
more men. However, the levels of CatK and collagen-turnover
markers were higher in patients with PeAF than in those with
PAF, even though the PeAF group was younger and included
more men, indicating that age- and sex-associated differences
did not inﬂuence the interpretation of our ﬁndings. In addition,
LAD size and the frequency of b-blocker intake were higher in
the AF group than in the control group. Furthermore, a
potential impact of these variations on CatK expression was
excluded by using multivariable and stepwise logistic models.
Fourth, it will also be necessary to investigate cardiovascular
events as clinical outcomes in future follow-up studies. Fifth,
further study will be also necessary to evaluate dose-
dependent beneﬁcial effects of olmesartan on CatK expression
and atrial remodeling in rabbit model.
Clinical Implication and Conclusions
Our observations show that increased plasma CatK levels are
closely linked to the presence of AF and to increased levels of
collagen turnover. Therefore, measurement of the circulating
CatK level could provide useful information for the evaluation
of atrial remodeling in patients with AF. In addition, our
ﬁndings conﬁrm and extend earlier work
19 linking the AT1R/
p38MAPK signaling pathway and the activation of NADPH
oxidase with AF. We showed that increases in CatK expres-
sion and activity were accompanied by local atrial changes in
Ang II/AT1R signaling pathway activation in the atrium with
AF. The antagonism of AT1R-mediated beneﬁcial effects on
atrial ﬁbrotic remodeling–related AF are likely attributable, at
least in part, to the attenuation of CatK expression and
activation induced by the AT1R/p38MAPK-dependent and
-independent signaling pathway activations.
Sources of Funding
This work was supported in part by grants from the Ministry of
Education, Culture, Sports, Science, and Technology of Japan
(24659385 to Dr Cheng; 23390208 to Dr Murohara), by the
International Natural Science Foundation of China (grant
81260068), and by the Ministry of Education, Science and
Technology of Korea (2012M3A9C6050507).
Disclosures
None.
References
1. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms
of atrial ﬁbrillation: a translational appraisal. Physiol Rev. 2011;91:265–325.
2. Corradi D, Maestri R, Macchi E, Callegari S. The atria: from morphology to
function. J Cardiovasc Electrophysiol. 2011;22:223–235.
3. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural
remodeling during atrial ﬁbrillation. Cardiovasc Res. 2002;54:230–246.
4. Fomovsky GM, Thomopoulos S, Holmes JW. Contribution of extracellular
matrix to the mechanical properties of the heart. J Mol Cell Cardiol.
2010;48:490–496.
5. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers.
Biochim Biophys Acta. 2000;1477:98–111.
6. Sasaki T, Kuzuya M, Nakamura K, Cheng XW, Hayashi T, Song H, Hu L,
Okumura K, Murohara T, Iguchi A, Sato K. AT1 blockade attenuates
atherosclerotic plaque destabilization accompanied by the suppression of
cathepsin S activity in apoE-deﬁcient mice. Atherosclerosis. 2010;210:
430–437.
7. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP,
Frederik P, van der Made I, Daugherty A, Sijbers AM, Fisher A, Long CJ, Saftig
P, Black D, Daemen MJ, Cleutjens KB. Disruption of the cathepsin K gene
reduces atherosclerosis progression and induces plaque ﬁbrosis but acceler-
ates macrophage foam cell formation. Circulation. 2006;113:98–107.
8. Cheng XW, Huang Z, Kuzuya M, Okumura K, Murohara T. Cysteine protease
cathepsins in atherosclerosis-based vascular disease and its complications.
Hypertension. 2011;58:978–986.
9. Spira D, Stypmann J, Tobin DJ, Petermann I, Mayer C, Hagemann S, Vasiljeva
O, Gunther T, Schule R, Peters C, Reinheckel T. Cell type-speciﬁc functions of
the lysosomal protease cathepsin L in the heart. J Biol Chem. 2007;282:
37045–37052.
10. Sun M, Chen M, Liu Y, Fukuoka M, Zhou K, Li G, Dawood F, Gramolini A, Liu PP.
Cathepsin-L contributes to cardiac repair and remodelling post-infarction.
Cardiovasc Res. 2010;89:374–383.
11. Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K, Nagata K,
Nishizawa T, Kobayashi M, Yamada T, Kim W, Sato K, Shi GP, Okumura K,
Yokota M. Superoxide-dependent cathepsin activation is associated
with hypertensive myocardial remodeling and represents a target for
angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008;173:
358–369.
12. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for
cysteine protease cathepsins in heart disease: focus on biology and
mechanisms with clinical implication. Circulation. 2012;125:1551–1562.
13. Lindholt JS, Erlandsen EJ, Henneberg EW. Cystatin C deﬁciency is associated
with the progression of small abdominal aortic aneurysms. Br J Surg.
2001;88:1472–1475.
14. Cheng XW, Kikuchi R, Ishii H, Yoshikawa D, Hu L, Takahashi R, Shibata R, Ikeda
N, Kuzuya M, Okumura K, Murohara T. Circulating cathepsin K as a potential
novel biomarker of coronary artery disease. Atherosclerosis. 2013;228:
211–216.
15. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, Hsu KL,
Tseng CD, Liau CS, Tseng YZ. Renin–angiotensin system gene polymorphisms
and atrial ﬁbrillation. Circulation. 2004;109:1640–1646.
16. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS, Hoit BD,
Keshelava G, Zhao H, Capecchi MR, Bernstein KE. Mice with cardiac-restricted
angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac
arrhythmia, and sudden death. Am J Pathol. 2004;165:1019–1032.
17. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, Kijima K,
Maruyama K, Masaki H, Moriguchi Y, Shibasaki Y, Kamihata H, Inada M,
Iwasaka T. Angiotensin II type 2 receptor is upregulated in human heart with
interstitial ﬁbrosis, and cardiac ﬁbroblasts are the major cell type for its
expression. Circ Res. 1998;83:1035–1046.
DOI: 10.1161/JAHA.113.000503 Journal of the American Heart Association 10
Cathepsin K and Atrial Fibrillation Fujita et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
H18. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of
angiotensin-converting enzyme inhibition on the development of the atrial
ﬁbrillation substrate in dogs with ventricular tachypacing-induced congestive
heart failure. Circulation. 2001;104:2608–2614.
19. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU,
Lendeckel U. Increased expression of extracellular signal-regulated kinase and
angiotensin-converting enzyme in human atria during atrial ﬁbrillation. JA m
Coll Cardiol. 2000;35:1669–1677.
20. Cheng XW, Okumura K, Kuzuya M, Jin Z, Nagata K, Obata K, Inoue A, Hirashiki
A, Takeshita K, Unno K, Harada K, Shi GP, Yokota M, Murohara T. Mechanism
of diastolic stiffening of the failing myocardium and its prevention by
angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol.
2009;54:47–56.
21. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K.
Angiotensin II antagonist prevents electrical remodeling in atrial ﬁbrillation.
Circulation. 2000;101:2612–2617.
22. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS,
Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external
cardioversion of long-standing persistent atrial ﬁbrillation. Results of a
prospective and controlled study. Eur Heart J. 2003;24:2090–2098.
23. ArndtM,LendeckelU,RockenC,NeppleK,WolkeC,SpiessA,HuthC,AnsorgeS,
Klein HU, Goette A. Altered expression of ADAMs (A Disintegrin And
Metalloproteinase) in ﬁbrillating human atria. Circulation. 2002;105:720–725.
24. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garﬁnkle M, Yusuf S, Connolly
SJ. Prevention of atrial ﬁbrillation with angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll
Cardiol. 2005;45:1832–1839.
25. McNamara RL, Brass LM, Drozda JP Jr, Go AS, Halperin JL, Kerr CR, Levy S,
Malenka DJ, Mittal S, Pelosi F Jr, Rosenberg Y, Stryer D, Wyse DG, Radford MJ,
Goff DC Jr, Grover FL, Heidenreich PA, Peterson ED, Redberg RF. ACC/AHA
key data elements and deﬁnitions for measuring the clinical management and
outcomes of patients with atrial ﬁbrillation: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Data Standards
(Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll
Cardiol. 2004;44:475–495.
26. Shimano M, Tsuji Y, Inden Y, Kitamura K, Uchikawa T, Harata S, Nattel S,
Murohara T. Pioglitazone, a peroxisome proliferator-activated receptor-gamma
activator, attenuates atrial ﬁbrosis and atrial ﬁbrillation promotion in rabbits
with congestive heart failure. Heart Rhythm. 2008;5:451–459.
27. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaka T,
Saka M, Kimata T, Noda A, Nagata K, Jin H, Shi GP, Iguchi A, Murohara T,
Yokota M. Elastolytic cathepsin induction/activation system exists in
myocardium and is upregulated in hypertensive heart failure. Hypertension.
2006;48:979–987.
28. Saygili E, Rana OR, Reuter H, Frank K, Schwinger RH, Muller-Ehmsen J, Zobel
C. Losartan prevents stretch-induced electrical remodeling in cultured atrial
neonatal myocytes. Am J Physiol Heart Circ Physiol. 2007;292:H2898–H2905.
29. Cheng XW, Kuzuya M, Nakamura K, Di Q, Liu Z, Sasaki T, Kanda S, Jin H, Shi
GP, Murohara T, Yokota M, Iguchi A. Localization of cysteine protease,
cathepsin S, to the surface of vascular smooth muscle cells by association
with integrin alphanubeta3. Am J Pathol. 2006;168:685–694.
30. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA,
Maliaraki NE, Lathourakis CE, Chlouverakis GI, Vardas PE. Extracellular matrix
alterations in patients with paroxysmal and persistent atrial ﬁbrillation:
biochemical assessment of collagen type-I turnover. J Am Coll Cardiol.
2008;52:211–215.
31. Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M, Nagashima K,
Mano H, Sonoda K, Kasamaki Y, Hirayama A. Impact of biomarkers of
inﬂammation and extracellular matrix turnover on the outcome of atrial
ﬁbrillation ablation: importance of matrix metalloproteinase-2 as a predictor of
atrial ﬁbrillation recurrence. J Cardiovasc Electrophysiol. 2010;22:987–993.
32. Kozawa E, Nishida Y, Cheng XW, Urakawa H, Arai E, Futamura N, Shi GP,
Kuzuya M, Hu L, Sasaki T, Ishiguro N. Osteoarthritic change is delayed in a
cathepsin K knockout mouse model of osteoarthritis. Arthritis Rheum.
2012;64:54–64.
33. Wei SG, Yu Y, Zhang ZH, Weiss RM, Felder RB. Mitogen-activated protein
kinases mediate upregulation of hypothalamic angiotensin II type 1 receptors
in heart failure rats. Hypertension. 2008;52:679–686.
34. Lee KW, Everett TH IV, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE.
Pirfenidone prevents the development of a vulnerable substrate for atrial
ﬁbrillation in a canine model of heart failure. Circulation. 2006;114:1703–
1712.
35. Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS.
Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metallo-
proteinases in rapid atrial pacing-induced atrial ﬁbrillation. J Mol Cell Cardiol.
2008;45:742–753.
36. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D,
Pfeiffenberger J, Rohl FW, Huth C, Ebert MP, Klein HU, Rocken C. Angiotensin II
receptor blockade reduces tachycardia-induced atrial adhesion molecule
expression. Circulation. 2008;117:732–742.
37. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents
glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1
receptor and NADPH oxidase. Hypertension. 2003;42:206–212.
38. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ,
Schotten U, Casadei B. Atrial sources of reactive oxygen species vary with the
duration and substrate of atrial ﬁbrillation: implications for the antiarrhythmic
effect of statins. Circulation. 2012;124:1107–1117.
DOI: 10.1161/JAHA.113.000503 Journal of the American Heart Association 11
Cathepsin K and Atrial Fibrillation Fujita et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
H